Table 3. Treatment for EBV-associated malignancies.

EBV-specific T cell activator	T cell source	Disease	CR, PR, remission, or disease free	References
LCL	Transplant donor derived	Post-HSCT PTLD	11/13	Rooney et al., 1995, 1998; Heslop et al., 1996, 2010
			10/14	Doubrovina et al., 2012
			1/1	Lucas et al., 1998
			3/4	Comoli et al., 2007
	Allogeneic	Post-HSCT PTLD	4/5	Doubrovina et al., 2012
		Post-HSCT viremia or EBV-LPD	9/10	Naik et al., 2016
		Post-SOT PTLD	15/31	Haque et al., 2007
	Autologous	Post-SOT PTLD	1/1	Khanna et al., 1999
Viral Ags from EBV, CMV, and ADV	Transplant donor derived	Post-HSCT PTLD	2/2	Naik et al., 2016
	Allogeneic	Post-HSCT viremia or EBV-LPD	1/2	Naik et al., 2016
APCs transduced with ADV vector encoding LMP1 and/or LMP2	Autologous or third party	Active EBV+ lymphoma; EBV+ lymphoma (in remission)	13/21; 27/29	Bollard et al., 2014

Abbreviations used: ADV, adenovirus; CR, complete response; LPD, lymphoproliferative disease; PR, partial response.